My BioCentury Inc pick this week focuses on Radiopharmaceuticals. Radiopharmaceuticals are on the brink of a groundbreaking milestone. Check out this insightful article from BioCentury discussing the advancements and potential impact of this emerging space. As the demand for innovative treatments continues to rise, the intersection of healthcare and technology presents incredible opportunities for growth and advancement. Stay informed and join the conversation around the future of radiopharmaceuticals! #Radiopharmaceuticals #HealthcareInnovation #Biotechnology #MedicalTechnology #BioCentury #MedicalAdvancements #HealthcareTrends #FutureOfMedicine

Have you booked your place yet for TIDES Europe 2024? Make sure to check out my colleague, Joanthan Fox's presentation on New LC-MS Approaches for RNA Therapeutics to Ensure Process Consistency and Product Quality 👉 Recent #RNA approvals underscore the critical need for robust analytical methods to monitor critical quality attributes (CQAs), ensuring control of manufacturing processes and product quality. Oligonucleotide mapping via #LCMS has proven effective for CQA assessment. However, traditional sample preparation and data handling can be time-consuming challenges. 🔬 We are excited to introduce novel sample preparation, data acquisition, and data processing workflows designed to produce fragment assignments for sgRNA and mRNA, including the measurement of key #CQAs. This innovative approach promises to streamline the process, enhancing efficiency and accuracy in RNA therapeutic development. 🔥 Join us to learn more about these cutting-edge techniques and how they can ensure process consistency and product quality in RNA therapeutics. #Biopharma #AnalyticalChemistry #Innovation https://lnkd.in/eT4jpPdh

📣 Heidelberg Pharma AG is pleased to announce the formal closing of the royalty purchase agreement with HealthCare Royalty for Zircaix®, signed earlier this month.📣 The funding will be used to further advance our proprietary toolbox of novel payloads and first-in-class Amanitin-based Antibody Conjugate pipeline, including lead candidate HDP-101 which is currently progressing in a Phase I/IIa study for the treatment of #multiplemyeloma. 📌 Read more via the link in the comments! 📌 We look forward to sharing further clinical updates at #AACR2024 in April. #ADC #ATAC #Financing

With Autolus Therapeutics obtaining their first FDA approval with AUCATZYL and Roche's recent acquisition of Poseida Therapeutics, Inc., excitement is building in the cell therapy space. But these milestones cannot be achieved without solid analytical evidence – especially translatable and robust potency assays.   The 4th Cell Therapy Potency Assay Summit will address the critical challenges of implementing current draft FDA guidance, optimizing assay development strategy and streamlining tech transfer processes. More details here: https://ter.li/d4mhky   👨🔬 Join a community of scientists including Briti Saha, PhD, Shawna Organ, PhD and Hui-wen Liu ⚙️ Participate in interactive workshops lead by Anthony Garcia, M.ScPh, Jorge S. Burns and Connie Tsai 👥 Network with brand-new speaker companies including Novartis, Resolution Therapeutics and BioNTech SE   Our $900 registration discount ends this Friday, December 6, take advantage of our lowest prices now! https://ter.li/ifwo6w #CellTherapy #FDAApproval #Biotech #PotencyAssays #QualityControl #TechTransfer #Biopharma #MedicalResearch #AnalyticalDevelopment

We’re thrilled to announce that the Biologics Department at BioRadius Therapeutic Research Pvt. Ltd. is officially part of the SOULCAP Initiative! A huge thank you to Ryan Brinkman for leading this groundbreaking effort and welcoming us on board. As a CRO specializing in pre-clinical studies, we understand the critical importance of standardizing flow cytometry data to enhance reproducibility, cross-study comparability, and regulatory compliance. This initiative will be a game-changer for scientists, enabling more accurate interpretation of cytometry data, fostering collaboration, and improving the reliability of cross-study analyses. It will also benefit regulators by establishing globally recognized standards, ensuring robust and consistent data to support decision-making in clinical and pre-clinical research. I’d also like to thank my colleague Smriti Mishra for her contributions and dedication, as well as Futuris Healthcare LLP for providing vital consumable support that keeps our work running smoothly. This collaboration wouldn’t have been possible without the incredible support of Dr. Senthil Thyagarajan our company’s director, whose guidance and vision continue to propel us forward. We’re excited to work alongside global leaders and experts to help shape the future of cytometry. Together, let’s set new standards for immunological research and data annotation! #RegulatoryCompliance #FlowCytometry #SOULCAP #Biologics #Standardization #DataAnnotation #PreClinicalResearch #CRO #BioRadius #FuturisHealthcare #immunology #cellbasedassays

👉 Did you know? In Lower Saxony, in the beautiful city of Göttingen , the Biotech company myriamed GmbH is located in this inconspicuous building not far from the Universitätsmedizin Göttingen and the Sartorius Campus. A biotech company with a world leading expertise on tissue engineering, drug development and drug screening. The myriamed GmbH proprietary human cell and engineered tissue models allow the simulation of health and disease in the dish. ✅ The myriamed platform technologies find broad applications in early stages of drug discovery and refinement of the most promising therapeutic candidates. ✅ Information gained from the advanced engineered tissue models can assist drug developers in defining safe and effective doses for first in human studies. ✅ Reduction in attrition rate and acceleration of clinical translation of the most promising therapeutic candidates to address pressing unmet medical needs is what myriamed strives for. With our products and services we offer unique support to the pharmaceutical and biotech industry from early preclinical to clinical stages of drug development to accelerate the clinical translation of novel safe and efficacious therapeutics. Learn more about our myriamed GmbH product and service portfolio: https://lnkd.in/erdnCgD5 Have you seen the all new myrImager we market together with SYNENTEC? myriamed GmbH: https://lnkd.in/dJGnhR_n SYNENTEC: https://lnkd.in/dQsNAi7g

We're thrilled to announce that our CEO, Christopher Hart, has shared valuable insights on unlocking the potential of oligonucleotide-based medicines (OBMs) in a new article published in Nucleic Acid Insights. In his piece, Chris discusses the importance of understanding the intricate relationship between sequence and chemistry in OBM development. This is a key step in transforming our approach from traditional drug discovery to innovative drug engineering. Chris highlights: - The need to recognize OBMs as fundamentally programmable drugs - The potential of modern AI/ML techniques in advancing OBM development - The importance of purpose-built data in overcoming current challenges At Creyon Bio, we're committed to reimagining the drug development paradigm. Our AI-enabled platform has already demonstrated clinical proof-of-concept, rapidly engineering and advancing a novel allele-selective rare disease medicine from concept to clinical application within one year. We invite you to read the full article and join the conversation on how we can collectively advance the field of oligonucleotide therapeutics: https://lnkd.in/eGndtqGb #BiotechInnovation #DrugDevelopment #ArtificialIntelligence #PrecisionMedicine BioInsights

📢 SciRhom GmbH Secures €63m Funding for Autoimmune Breakthrough German iRhom2-targeted antibody specialist SciRhom GmbH has closed an oversubscribed €63m Series A financing. The funding will be used to provide clinical proof of concept in autoimmune disorders. The financing was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners. New investor Bayern Kapital and existing investors iHigh-Tech Gründerfonds HTGF and PhiFund Ventures also participated. The first clinical study evaluating SR-878, a humanised monoclonal antibody targeting iRhom2, is expected to start dosing in H2/2024. #BioprocessUpdates #SciRhomGmbH #SeriesAfinancing #clinicaltrial #autoimmunedisorders #biotechstartup #antibodytherapy #investmentround #Germaninnovation #healthtech #biopharmaceuticals #innovativetherapeutics #medicalresearch #iRhom2targetedantibody #BayernKapital #clinicalproof ▷ Read the full article here: 📎 https://lnkd.in/d5Rjc2dU

The top regional #healthcare and #biotech news for December 13th via the Big4Bio newsletters: San Diego: Exec Changes at Boundless Bio; Palisade Bio Prices $5M Offering; Upcoming Events https://lnkd.in/gszFjGvF SF Bay: BeiGene Inks $150M Deal; Gilead Sciences Names CMO; Alessa Therapeutics, Inc. Closes $15M https://lnkd.in/geqByjkM Seattle: Aptevo Therapeutics Inc Receives Funding Boost; Bill & Melinda Gates Foundation $5.9M Funds for Diagnostics Development; Upcoming Events https://lnkd.in/gqbQTZ8c Los Angeles: University of Southern California Secures $2.7M NIH Grant; MaxScientific's Innovation in Anti-Aging; Upcoming Events https://lnkd.in/gJtFqk_u Boston: iSpecimen Hires CEO; Layoffs at Editas Medicine; iTeos Therapeutics Drops Cancer Candidate; Keros Therapeutics Shares Collapse https://lnkd.in/gnf-gihH Philadelphia: INOVIO Pharmaceuticals, Inc. Prices $30M Offering; Transcenta's TNBC Data; Zelira Therapeutics' Path to Approval https://lnkd.in/gM8W4kPf Capital Region: Revolo Biotherapeutics Reveals Preclinical Data; Bringing Infectious Disease Tests to Market; Hot Investor Mandates https://lnkd.in/gHpgp3nH NYC: Pfizer's Blockbuster Scores; Intercept Pharmaceuticals Drug Faces Scrutiny; Padlock Therapeutics, Inc., Bristol Myers Squibb Dispute; HUTCHMED Hits Milestone https://lnkd.in/gJFm8CkV

𝗧𝗵𝗲 𝗣𝗵𝗮𝗿𝗺𝗮 𝗡𝗲𝘄𝘀 𝟮𝟬𝟮𝟰 Decoding the News: Key Insights from the News Article ⬇ Below are the links to the respective news articles: 1. Telix spends up to $82M to boost isotope production with ARTMS buyout https://lnkd.in/g_sWVX55 2. Biotech IPOs heated up to start 2024. Will the surge last https://lnkd.in/gZbdKnkA 3. Sionna raises another $182M to challenge Vertex in cystic fibrosis https://lnkd.in/g-2QEg9E 4. How CDMO Wacker Biotech is inspiring innovation in mRNA therapeutics https://lnkd.in/gQC8gHxB 5. Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit https://lnkd.in/gYMUkn5f P.S. Comment below with the latest pharma/biotech news you came across #pharma #cdmo #biotech